Case Report
Copyright ©2014 Baishideng Publishing Group Co.
World J Gastroenterol. May 7, 2014; 20(17): 5165-5170
Published online May 7, 2014. doi: 10.3748/wjg.v20.i17.5165
Table 1 Hepatitis B virus reactivation in patients with lymphoma and treated with entecavir
AuthorPatients (n)Hematologic malignancyPre-treatment HBV markersProphylaxis with anti-viral drugsRituximab-based regimenTime of HBV reactivation (during/after anti-tumor therapy)Outcome (alive/died)HBsAg clearance (yes/no)
Ferreira et al[22]1DLBCLHBsAg-, anti-HBs+, anti-HBc-NoYes0/10/1NR
Niitsu et al[14]6DLBCLHBsAg-NoYes2/45/11NR
Chung et al[15]1DLBCLHBsAg-, anti-HBs+, anti-HBc+NoYes1/00/10/1
Lee et al[16]1FLHBsAg-, anti-HBs+NoYes1/01/0NR
Stange et al[17]2B cell lymphomaunknownNoYes2/01/1NR
Brost et al[11]4AML and lymphomaUnknown for all1 Yes, 3 NoNo2/23/13/1
Sanchez et al[12]1CLLHBsAg-NoYes0/11/0NR
Colson et al[13]1B cell lymphomaHBsAg-, anti-HBs-, anti-HBc+NoYes1/01/0NR
Mimura et al[18]3B cell lymphomaHBsAg+YesYes0/33/0NR
Matsue et al[19]5B cell lymphomaHBsAg-NoYes0/55/01/4
Wu et al[20]1DLBCLHBsAg-, anti-HBc+NoYes0/10/10/1
Fukushima et al[21]2NHL, DLBCLHBsAg-NoYes0/22/01/1